55 A recent study has highlighted the transformative potential of predictive biomarker testing in managing advanced-stage non-small cell lung cancer (NSCLC). As personalised medicine continues to evolve, this research underscores the importance of molecular diagnostics in tailoring treatments to individual patients, promising significant improvements in clinical outcomes. The findings were published in the journal The Lancet Regional Health. The study details the rapid expansion in the number of clinically relevant biomarkers for advanced-stage NSCLC. These biomarkers are crucial for determining the most effective targeted therapies. For now, the European Society for Medical Oncology (ESMO) says that molecular tests should look for key biomarkers like EGFR, KRAS, BRAF, and MET mutations, as well as ALK, ROS1, RET, and NTRK1/2/3 fusions. The presence of these biomarkers can dictate the use of specific targeted therapies that have been shown to improve patient outcomes significantly. Emerging biomarkers are also playing a critical role in predicting responses to treatment and understanding resistance mechanisms. For instance, having PIK3CA mutations in EGFR-mutated NSCLC has been linked to worse survival rates, which stresses the need for thorough molecular profiling. The study advocates for the routine use of large-panel next-generation sequencing (NGS) in all patients with advanced-stage NSCLC. NGS allows for the simultaneous testing of multiple genes, providing a comprehensive molecular profile of the tumour. This approach is not only more cost-effective compared to sequential single-gene testing but also ensures that all clinically relevant biomarkers are identified, enabling more precise treatment decisions. A number of large NGS panels, including the TruSight Oncology 500, FoundationOne CDx, and Agilent SureSelect Cancer CGP assay, are praised for the large number of clinically important genes they cover. These panels can find a lot of different types of mutations, including single nucleotide polymorphisms, copy number changes, homologous recombination deficiency signatures, microsatellite instability, rearrangements, and the number of mutations in tumours. The study recommends the centralisation of molecular testing within dedicated, expert laboratories as part of regional oncology networks. This centralisation ensures cost-effectiveness, equal access to advanced diagnostics, and the consistent interpretation of complex molecular data. A centralised Molecular Tumour Board within these networks can facilitate optimal treatment decisions, particularly for patients with rare or complex mutations. This model promotes regional collaboration, continuous educational development, and the establishment of national research databases. It is essential for keeping pace with the rapidly evolving field of oncology and ensuring that all patients have access to the latest diagnostic and therapeutic advances. The findings underscore the necessity of incorporating comprehensive molecular profiling into routine clinical practice for advanced-stage NSCLC. By identifying all relevant biomarkers, clinicians can make more informed treatment decisions, potentially improving patient outcomes and extending survival. The study also highlights the importance of testing for biomarkers associated with resistance to targeted therapies. For example, NGS can find ways that osimertinib does not work in EGFR-mutated NSCLC, like MET amplification and RET fusions, which helps doctors choose other treatments. As the landscape of cancer treatment continues to evolve, the number of clinically relevant biomarkers is expected to grow. The study calls for the integration of new and emerging biomarkers into routine testing protocols to ensure that patients receive the most effective and personalised treatments available. The development of new targeted therapies and their incorporation into clinical trials will further enhance the precision of cancer treatment. Research and clinical trials that are still going on, like the ones looking into how well trastuzumab deruxtecan works for ERBB2-mutated NSCLC, are very important for giving patients more treatment options.